Join Growin Stock Community!

Evommune, inc.EVMN.US Overview

US StockHealthcare
(No presentation for EVMN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EVMN AI Insights

EVMN Overall Performance

EVMN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EVMN Recent Performance

0.12%

Evommune, inc.

0.05%

Avg of Sector

-0.31%

S&P500

EVMN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EVMN Key Information

EVMN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EVMN Profile

Price of EVMN

EVMN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EVMN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.02
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
63.05
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
96.25%
Net Margin
-260.40%
Revenue Growth (YoY)
233.33%
Profit Growth (YoY)
266.95%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.02
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
63.05
PB Ratio
-
Price-to-FCF
-
Gross Margin
96.25%
Net Margin
-260.40%
Revenue Growth (YoY)
233.33%
Profit Growth (YoY)
266.95%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is EVMN's latest earnings report released?

    The most recent financial report for Evommune, inc. (EVMN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EVMN's short-term business performance and financial health. For the latest updates on EVMN's earnings releases, visit this page regularly.

  • How much cash does EVMN have?

    At the end of the period, Evommune, inc. (EVMN) held Total Cash and Cash Equivalents of 28.23M, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does EVMN go with three margins increasing?

    In the latest report, Evommune, inc. (EVMN) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -133.28%%, and net margin of -124.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess EVMN's profit trajectory and future growth potential.